We investigated the effects of zinc supplementation on clinical observations in chronic hepatitis C patients receiving pegylated interferon (PEG-IFN) ␣ -2b plus ribavirin combination therapy. Patients were randomly allocated to receive 150 mg polaprezinc (zinc group, n ϭ 11) or no supplement (control group, n ϭ 12) daily in addition to PEG-IFN ␣ -2b plus ribavirin therapy and 300 mg vitamin E and 600 mg vitamin C supplementation daily for 48 wk. Among the patients who continued treatment, the serum alanine aminotransferase (ALT) level at 12 wk in the zinc group was significantly lower than that in the control group. All patients in the zinc group (9/9) and 67% (8/12) of the control patients at 24 wk, and all patients in the zinc group (7/7) and 60% (6/10) of the control patients at 48 wk showed a decrease in serum ALT levels to within the normal range (7-44 U/L). HCV RNA disappeared in all patients (7/7) in the zinc group and in 8 of 10 control patients at 48 wk. Polaprezinc supplementation decreased plasma thiobarbituric acid reactive substances and prevented the decrease of polyunsaturated fatty acids of erythrocyte membrane phospholipids. No significant differences were observed in the dosage of medicines or other clinical data during the treatment. These observations indicate that polaprezinc supplementation may have induced some antioxidative functions in the liver which resulted in reduced hepatocyte injury during PEG-IFN ␣ -2b plus ribavirin therapy.
Increased oxidative stress has been shown to accompany chronic hepatitis ( 1, 2 ) , and it promotes liver fibrosis and hepatocellular carcinoma. Various factors, including hepatocellular iron accumulation ( 3 , 4 ) and the direct effect of the hepatitis C virus (HCV) core protein ( 5 ) , are currently considered to be the causes of oxidative stress, in addition to reactive oxygen species production related to the immune response ( 6 , 7 ) . Combination therapy using pegylated interferon (PEG-IFN) and ribavirin is reported to induce a higher sustained viral response ( 8 ) . However, adverse effects such as hemolytic anemia resulting from the oxidative damage of membranes ( 9 ) , fever, and appetite loss are common in combination with interferon and ribavirin therapy. A reduced dietary antioxidant intake associated with a lack of appetite may decrease the antioxidant capacity of patients. In our previous studies, vitamin E and C supplementation during IFN ␣ -2b plus ribavirin therapy prevented a decrease in the eicosapentaenoic acid (EPA) level of mononuclear cell phospholipids ( 10 ) , and EPA supplementation with vitamins E and C prevented a decrease in the lymphocyte counts during IFN ␣ -2b plus ribavirin therapy ( 11 ) . Reduced levels of plasma ␣ -tocopherol and ascorbic acid in hepatitis C patients were also observed ( 10 ) .
Zinc is known to be an essential trace element which is a component of many enzymes related to the metabolic processing of nucleic acids and proteins, the immune system ( 12 ) , and other biological systems. Decreased serum zinc levels have been observed in acquired conditions, including chronic inflammation, infectious diseases, malnutrition, alcoholism, and chronic liver disease ( 13 ) , and also in elderly individuals ( 14 ) . Polaprezinc N -(3-aminopropionyl)-L -histidinato zinc, a complex of zinc and L -carnosine, is a medicine for gastric ulcers that contains zinc and has antioxidant ( 15 ) and immunomodulatory effects that protect cellular membranes. Several studies have reported the efficacy of zinc and polaprezinc supplementation in animal models (16) (17) (18) (19) (20) , patients with chronic liver disease E-mail: yasuko@fhw.oka-pu.ac.jp ( 21 ) , and patients undergoing interferon therapy (22) (23) (24) . However, little is known about the effect of polaprezinc supplementation during PEG-IFN and ribavirin therapy. We investigated the effects of polaprezinc supplementation on the clinical observations and fatty acid composition of erythrocyte membrane phospholipids in chronic hepatitis C patients receiving PEG-IFN ␣ -2b plus ribavirin combination therapy.
PATIENTS AND METHODS
Patients. Twenty-three chronic hepatitis C patients with genotype 1b and high viral load ( м 10 5 IU/mL) (12 males and 11 females; average age 58.0 Ϯ 2.3 y) treated at Kagawa Prefectural Central Hospital were enrolled in this study. Patients with detectable hepatitis B virus surface antigen, other potential causes of chronic liver disease, human immunodeficiency virus infection, poorly controlled diabetes mellitus, or cardiovascular disease were excluded.
Study design. We obtained written informed consent from all patients, and randomized them into a zinc supplementation group (zinc group: 6 males and 5 females, average age 59.5 Ϯ 4.1 y) and no supplementation group (control group: 6 males and 6 females, average age 56.7 Ϯ 2.4 y). Patients in the zinc group received 150 mg of polaprezinc, equivalent to 33.9 mg of zinc (Promac, one packet contains 75 mg of polaprezinc, Zeria Pharmaceutical Co., Tokyo, Japan) twice a day for 48 wk. All patients received 300 mg of vitamin E (Juvela, one tablet contains 50 mg of tocopherol acetate, Eisai, Tokyo, Japan) and 600 mg of vitamin C (Cinal, one packet contains 200 mg of ascorbic acid, Shionogi & Co., Osaka, Japan) orally, in addition to injections of PEG-IFN ␣ -2b (PegIntron, ScheringPlough K.K., Osaka, Japan) once a week for 48 wk, plus daily oral ribavirin (Revetol, Schering-Plough K.K.) for 48 wk. No significant differences were observed in the distribution of the histological diagnosis for grading inflammation or for staging fibrosis at the baseline. The patients were required not to take zinc, iron, or other antioxidant supplements for the treatment period.
Blood samples were obtained from each patient immediately before the initiation of therapy (0 wk) and at 4, 8, 12, 24 , and 48 wk after the start of therapy.
This experiment was designed in accordance with the principles of the Declaration of Helsinki of the World Medical Association and was approved by the Ethics Committee of Kagawa Prefectural Central Hospital.
Analytical methods. We determined routine clinical laboratory parameters, such as red blood cell, white blood cell, and platelet counts, hemoglobin, alanine aminotransferase (ALT), aspartate aminotransferase (AST), and zinc concentrations. Flow cytometry was used to characterize and distinguish CD 4 ϩ T cells as T helper (Th) 1 or Th2, as defined by their cytokine production (IFN-␥ and IL-4, respectively) ( 25 ) . To determine the rate of blastogenesis of lymphocytes by phytohemagglutinin (PHA), after adding PHA to isolated lymphocytes, the value of the ratio of 3 H-thymidine incorporation into PHA-treated cells to the control without PHA was calculated (SI; stimulation index) ( 26 ) .
Plasma was separated after the centrifugation of blood samples containing heparin at 1,600 ϫ g for 15 min at 4˚C. The erythrocyte layer was drawn off into another tube and washed 3 times with saline (4˚C) for determination of the fatty acid composition in erythrocyte membrane phospholipids. All samples were stored at Ϫ 80˚C until assayed.
The ␣ -tocopherol concentration of plasma was determined according to a modification of the method of Milne and Botnen ( 27 ), as we described previously ( 10 ) .
Total lipids were extracted from erythrocyte membranes suspended in saline by the modified method of Bligh and Dyer ( 28 ) . Phospholipids were separated by one-dimensional thin-layer chromatography using silica gel plates (Silica Gel 60; Merck, Darmstadt, Germany) and a solvent system of petroleum ether : ethyl ether : acetic acid (80 : 20 : 1, v/v). The spots corresponding to phospholipids were scraped from the plates and transmethylated for 2 h at 90˚C using acetylchloride : methanol (5 : 50, v/v). A known amount of heptadecanoic acid (17 : 0) was used as an internal standard. Fatty acid methyl esters were analyzed by gas-liquid chromatography (Model GC-14A; Shimadzu, Kyoto, Japan), as described previously ( 29 ) .
Plasma thiobarbituric acid reactive substances (TBARS), primarily malondialdehyde, was measured according to the method described by Yagi ( 30 ) .
Statistical analysis. Values are expressed as the means Ϯ standard errors (SE). Repeated measures ANOVA followed by Dunnett's test, Student's t test, Fisher's exact test, or the Chi square test with Yates' correction was conducted to analyze the data as appropriate. All p values are two-tailed and significance was set at p Ͻ 0.05.
RESULTS

Completion of the assigned therapy
One patient in the zinc group discontinued the treatment between week 8 and 12 because of epistaxis. One patient in the zinc group changed hospitals after 16 wk. Two patients in each group discontinued the treatment between week 24 and 37 under advisement of a doctor, because they had no virologic response. Consequently, 21 patients (9 in the zinc group and 12 in the control group) were analyzed until 24 wk, and 17 patients (7 in the zinc group and 10 in the control group) were analyzed at the end of therapy. We divided the results into changes in clinical data until 24 wk for the early and middle period, and response to the therapy at 48 wk, and examined them.
Changes in clinical data until 24 wk
Nine subjects in the zinc group and 12 in the control group could continue the treatment until 24 wk. No significant differences were observed in the distribution of the histological diagnosis for grading inflammation or for staging fibrosis at the baseline (Table 1 ) and the dose of PEG-IFN ␣ -2b ( g/kg body weight) or ribavirin (mg/kg body weight) during treatment between the two groups.
Serum ALT levels decreased significantly after 4 wk in both groups (Table 2 ). However, the ALT level at 12 wk in the zinc group was significantly lower than that in the control group ( p Ͻ 0.05). Figure 1 shows the changes in the ALT level in each patient during treatment. All patients in the zinc group showed a decreased ALT level to less than 35 U/L at 24 wk (Fig. 1B) , but only 8 of 12 patients (67%) in the control group improved to within the normal range (7-44 U/L) (Fig.  1A) . The serum AST level was significantly improved after 4 wk in the zinc group, but not in the control group.
The red blood cell count and hemoglobin level decreased at 4 wk in both groups, and thereafter, these levels further decreased gradually and no significant difference was observed between the groups until 24 wk of therapy. The white blood cell, neutrophil, and lymphocyte counts decreased significantly in both groups. Plasma ␣-tocopherol levels significantly increased at 4 wk and were maintained at high levels throughout supplementation in both groups. The plasma TBARS levels were significantly decreased at 4 (pϽ0.01) and 8 (pϽ0.01) wk in the zinc group, but not in the control group. The ratio of Th1 to Th2 and the serum zinc level did not change significantly during therapy in either group, but the serum zinc level in the zinc group was higher at 8 wk (pϽ0.01) than that in the control group. SI in the PHA-induced lymphocyte blast formation test increased significantly after 12 wk in both groups.
Fatty acid compositions of erythrocyte membrane phospholipids until 24 wk
Changes in the fatty acid composition of phospholipids of erythrocyte membranes during therapy are presented in Table 3 . In the control group, saturated fatty acids (SFA) increased at 4 (pϽ0.05) and 8 (pϽ0.05) wk, and polyunsaturated fatty acids (PUFA) (pϽ0.01) and the PUFA/SFA molar ratio (pϽ0.05) decreased at 4 wk, but no significant changes were observed in the zinc group during treatment. The percentage of variation in PUFA/SFA molar ratio was higher in the zinc group at 8 wk (pϭ0.067), as compared with the starting values (zinc group: Ϫ5.2, 38.5, 31.5 and 40.0%; controls: Ϫ23.1, Ϫ20.6, Ϫ0.8 and 24.1% at 4, 8, 12 and 24 wk). 
Response to PEG-IFN ␣-2b plus ribavirin therapy at the end of therapy
Seven subjects in the zinc group (4 males and 3 females, average age 65.4Ϯ1.3 y) and 10 in the control group (5 males and 5 females, average age 55.9Ϯ2.5 y) could continue the treatment for 48 wk. HCV RNA disappeared in all patients in the zinc group and in 8 of 10 control patients at 48 wk. All zinc-supplemented patients showed a decrease in the ALT level to less than 30 U/L at 48 wk, but only 6 of 10 patients (60%) in the control group improved to within the normal range. Among the 4 control patients (3 in grade 1 and one in grade 2 of inflammation grade at the start of therapy) who did not show improved ALT levels to within the normal range at 48 wk, 2 patients had viral clearance before 12 wk of treatment (Fig. 1A) . Sixty-seven percent of zinc-supplemented patients and 50% of control patients who had HCV RNA disappear at 48 wk maintained the negative for HCV RNA at 12 wk after completion of therapy.
DISCUSSION
In the present study, we observed significant decreases of serum transaminase activities in chronic hepatitis C patients who received daily supplementation of 150 mg of polaprezinc during combination therapy comprising PEG-IFN ␣-2b plus ribavirin. The increased ALT levels during therapy may have been related to hepatocyte injury, because there was no relationship between the ALT level and viral disappearance, the histological diagnosis for grade of inflammation at the start of therapy or other clinical data.
Zinc is absorbed mainly in the duodenum and jejunum and transported to the liver via the portal vein after combining with albumin. Therefore, hepatocytes may be exposed to higher levels of zinc than other tissues during zinc supplementation. Several studies have demonstrated the antioxidant properties of zinc. One of the mechanisms of antioxidation induced by long-term zinc administration is the induction of metallothioneins (MTs) in different organs such as the liver, kidney, and intestine (31) . In addition, MT-mRNA and MT protein are also induced by interferon, and this induction is influenced by the zinc status in the mouse liver (32). Takagi et al. (23) and Nagamine et al. (24) reported that polaprezinc (150 mg/d) supplementation enhanced the response to IFN ␣ mono-therapy in chronic hepatitis C patients with genotype 1b and a high viral load, and they concluded that the induction of MT resulted in increased antioxidative effects in the liver. Ko et al. (22) showed that zinc gluconate administration (equivalent to 50 mg of zinc daily) reduced the side effects of IFN ␣-2a plus ribavirin therapy, despite the absence of a beneficial effect on virologic responses. The beneficial effect on virologic responses was not observed in this trial with polaprezinc supplementation, but the increased antioxidant ability may protect against hepatocyte injury during therapy. Polaprezinc supplementation decreased plasma TBARS concentration and prevented the decrease in erythrocyte PUFA levels in the present study. These results may explain that polaprezinc prevented hepatic lipid peroxidation during treatment. Although our data were only from blood samples, some animal studies (18, 19) have reported zinc administration induces increased hepatic MTs and decreased hepatic TBARS, and the fatty acid composition in human erythrocyte membrane phospholipids resembles that of liver phospholipids (33) .
Our previous study (10) showed that daily vitamin E (500 mg) and C (750 mg) supplementation had no significant effect on ALT level improvement after 4 wk of IFN ␣-2b plus ribavirin therapy compared with that in no-vitamin-supplementation groups, which resulted in increased plasma ascorbic acid levels that reached a plateau of a 1.6-fold increase compared to the basal level after 2 wk. The difference in the type of interferon and the dosage method may explain the observed differences in the effects on ALT levels during therapy.
Zinc is trace element essential for the immune system, and is involved in T cell development and the zincmediated activation of monocytes and T cells. One of the mechanisms of interferon and ribavirin antiviral effects has been postulated to be that these agents serve as immunomodulators that enhance the production of type 1 cytokines (34). In addition, zinc deficiency is correlated with decreased productions of type 1 cytokines and IFN ␣ by leukocytes in healthy elderly persons. One possible explanation for the antiviral effect of polaprezinc which has been reported (23, 24) may be through regulation of the immune system, but we did not observe a difference in the rate of viral disappearance, or in the ratio of Th1 to Th2 in our study.
In conclusion, polaprezinc supplementation may have induced some antioxidative functions in the liver which resulted in reduced hepatocyte injury during PEG-IFN ␣-2b plus ribavirin therapy.
